Dr. Marcus MreyenHead of Business Development
Bi and multispecific antibodies are new artificially designed molecule formats evolving out of the therapeutic success of traditional antibody formats, with bivalent and monospecific constructions. To make the classical antibody biologic even more efficient and specific the design of bi and multispecific functionality in new IgG-like or non-IgG like formats has strongly increased and has already lead to approved therapeutics like Removab® (catumaxomab), Blincyto® (blinatumomab).
Kind of formats:
Bispecific antibodies can be divided into two major classes, those bearing an Fc region and those lacking an Fc region. The latter are generally smaller than the IgG and IgG-like bispecific molecules comprising an Fc. These new formats like for example CrossMab structures with a knob-into-hole design bear new analytical challenges to monitor heavy chain (HC) Dimer elimination, HC heterodimers or any HC-LC mispairing (LC, light chain).
These new formats comprise:
Analytical support throughout bi and multispecific antibody development
Protagen Protein Services has extensive experience in analysis of different antibody formats and can successfully support you with:
PPS provides individual analyses or a comprehensive characterization package customised to suit your requirements and to provide data required by the regulatory authorities for bispecific antibody analysis like:
Protagen Protein Services (PPS) has extensive experience in analysis of different protein classes and other formates and can successfully support you with a broad range of services:
Read more to the individual analytical services here